The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · May 2020
Randomized Controlled Trial Comparative StudySafety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
New glucose-lowering medications need to be investigated in east Asian populations, as the clinical characteristics of type 2 diabetes differ between western and east Asian patients. The PIONEER 10 study aimed to evaluate the safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes. ⋯ Novo Nordisk.
-
Lancet Diabetes Endocrinol · May 2020
Randomized Controlled TrialDose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo and a subcutaneous GLP-1 receptor agonist in a Japanese population. ⋯ Novo Nordisk.
-
Lancet Diabetes Endocrinol · May 2020
Editorial CommentObesity-related stigma-hiding in plain sight.